[Erythropoietin improved anemia in a case of multicentric Castleman's disease].
Severe anemia A 37 year-old male with therapy resistant multicentric Castleman's disease (MCD) anemia was treated by subcutaneous injection of erythropoietin. Although immunoglobulin and CRP concentration increased, anemia obviously improved with hemoglobin levels increasing from 4.8 g/dl to 8.5 g/dl without any side effects. Colony assay revealed that the bone marrow mononuclear cells responded to erythropoietin in a dose dependent manner. The mechanism of anemia of MCD is not clearly understood, and treatment is sometimes very difficult. There is no other previous report concerning erythropoietin as a treatment for anemia in MCD.
Otsubo
H
H
Department of Internal Medicine (II), Jikei University School of Medicine.
Kaito
K
K
Yoshida
M
M
Shimada
T
T
Masuoka
H
H
Nishiwaki
K
K
Saeki
A
A
Sakamoto
M
M
Sekita
T
T
Kobayashi
M
M
D000328:Adult; D000740:Anemia / Q000628:therapy*; D005871:Castleman Disease / Q000150:complications*; D015672:Erythroid Precursor Cells / Q000187:drug effects; D004921:Erythropoietin / Q000627:therapeutic use*; D006801:Humans; D007279:Injections, Subcutaneous; D008297:Male
D004921:Erythropoietin